Form 4 for KURA Kura Oncology, Inc.
Accepted 2026-03-25 00:00:00 ET · period of report 2026-03-23 · accession 0001193125-26-122938 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-25 | 2026-03-23 | KURA | WILSON TROY EDWARD | Pres, CEO, Dir | M - OptEx | $6.15 | +6,103 | 435.5K | +1% | +$37.5K |
| D | 2026-03-25 | 2026-03-23 | KURA | WILSON TROY EDWARD | Pres, CEO, Dir | M - OptEx | $0.00 | +6,103 | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-23 | M | A | 6,103 | $6.15 | 435,456 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-03-23 | M | A | 6,103 | $0.00 | 0 | D | $6.15 · — to 2027-01-22 | 6,103 Common Stock | (F2) This option is fully vested. |